Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 12/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 5/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.41 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.41 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | KIT | P10721 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1942556 | 0.92 | AURKA (0.46) | AURKAAURKBMETMAPK14CSF1R | |
| SCHEMBL1942543 | 0.90 | AURKA (0.51) | AURKAMETCSF1RPDGFRBKIT | |
| SCHEMBL29915092 | 0.90 | AURKA (0.51) | AURKAMETCSF1RPDGFRBKIT | |
| SCHEMBL1940774 | 0.89 | AURKA (0.51) | AURKAAURKBMETMAPK14 | |
| SCHEMBL1942157 | 0.83 | AURKA (0.51) | AURKAAURKBMET | |
| SCHEMBL1942218 | 0.81 | AURKA (0.55) | AURKAAURKBMET | |
| SCHEMBL14624135 | 0.81 | AURKA (0.45) | AURKAAURKBMETMAPK14 | |
| SCHEMBL1733758 | 0.80 | AURKA (0.62) | AURKAAURKBMET | |
| SCHEMBL1942051 | 0.80 | AURKA (0.51) | AURKAAURKBMETNTRK2PDGFRA | |
| SCHEMBL1734506 | 0.79 | AURKA (0.56) | AURKAAURKBMETCSF1RPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899346-B1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-15 | — | — | EP | claimed |
| US-7405213-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | claimed |
| US-20070004733-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | claimed |
| EP-1899346-B1 | PYRROLOTRIAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-15 | — | — | EP | disclosed |
| US-7405213-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405213-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405213-B2 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| US-20070004733-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004733-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
| US-20070004733-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004733-A1 | Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith | MAP3K20, PRKDC, MAP3K2 | AURKA 499/4885AURKB 342/4885MET 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.